Precision drug finding! "Wide-ranging Genetic Test Wins National Innovation Award
CEO H.K. Chen said that he will continue to promote precision medicine in the future so that the public can have a better understanding of genetic testing
According to statistics, one person suffers from cancer every five minutes in China, and the demand for high-precision genetic testing for cancer is growing. Domestic genetic testing company, Action Genetics, has launched the "Extensive Cancer Genetic Test", which utilizes cutting-edge genetic testing technology and professional biomedical and biological information analysis to find medication options for advanced cancer patients. The test won the 2018 National Innovation Award and is currently applying for FDA IVD in vitro diagnostic device certification.
"Cancer Genetic Testing" Award: A Great Leap Forward in Precision Medicine
Chen Huajian, the CEO of the award-winning genetic testing company, said that this year's winner of the National Innovation Award, the "Precision Medicine Award", was not only the first time that the judges recognized the product's technology, but also the first time that the company was awarded the "Precision Medicine Award".
Advanced Mode
The newest addition to our portfolio of products is our newest addition to our portfolio of products.
Chen Hua-key explained, they have more than 15 years of experience in the pharmaceutical industry, biomarkers and medical information professional field, in addition to the American Academy of Pathology (CAP) certified laboratories in Taiwan, and in the country's major hospitals to provide a full range of genetic testing technology to assist, at the same time, in Singapore, Japan, Hong Kong and mainland China have completed the relevant planning, the award has greatly enhanced their professional status in the field of precision medicine in Asia, but also in the future, the company will continue to promote the development of the industry. This award also greatly enhances their professional status in the field of precision medicine in Asia.
14 Developing treatment strategies in 14 80% of patients with advanced cancer benefit
Prevalent Cancer Genetic Test is a next-generation sequencing (NGS) test that detects a wide range of 440 genes related to cancer medications in a single test on a cancer tissue exam, and provides targeted therapy, immunotherapy, and treatment for cancer patients in a single 14-day period.
Data Ready is a video game that allows users to easily and intuitively access the full suite of multimedia content that is available to the public.
Additionally, we are able to provide additional medication recommendations for patients with advanced cancer, recurrent and metastatic cancers, advanced cancers that require differential diagnosis, cancers that have failed to respond to multiple lines of therapy, and cancers that are rare or of unknown origin.
Biomarker research has been recognized by the US as a way to improve immunotherapy
Chen Hua-key, CEO of the company, said that although immunotherapy is a popular treatment option for cancer, and there is a chance of a cure, the response rate of immunotherapy to tumors is only about 25%, and it is prone to autoimmune side effects, as well as the price of the treatment, which makes it more costly. Therefore, the selection of cancer patients with a high response rate to immunotherapy through effective biomarkers is also a direction of precision medicine that can effectively improve the success rate in the future.
Chen Hua-keen said that in May of this year, their algorithm for accurately predicting immunotherapy efficacy was favored by the U.S. Agency for Cancer Research and selected to participate in the development of the newest international immunotherapy evaluation standard - Tumor Mutation Burden (TMB) research program, as the only Asian genetic testing company outside of the U.S. The results of the study, which were released in the first phase, were much closer to those of TMB, and the results of the study were much closer to those of TMB. In the first phase of the study, the results were closer to the standardized values than any other testing company, making it the new generation of Asia's brightest.
In addition to the ongoing collaboration with domestic and international hospitals to help physicians develop more accurate medical strategies through genetic testing, CEO Hua-Keun Chen said they have also accumulated a large amount of genetic testing data that can be used by international pharmaceutical companies as a reference for drug development. In addition, the company is also actively cooperating with the technology industry to develop a genetic testing chip for IVD in vitro diagnostic equipment development, and is currently applying for U.S. FDA certification.
LINE@ ID:@ Subscribe to the Healthy Living AV channel for easier reading of health knowledge: /beauty/article/40470 Keywords: Chen Huajian, Extensive Cancer Genetic Testing, National Innovation Award, CAP-accredited labs, Next-Generation Sequencing, Providing Drug Options for Patients with Advanced Cancer.